预约演示
更新于：2024-12-24
Vildagliptin
维格列汀
更新于：2024-12-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2007-09-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H25N3O2 |
InChIKeySYOKIDBDQMKNDQ-XWTIBIIYSA-N |
CAS号274901-16-5 |
关联
308
项与 维格列汀 相关的临床试验TCTR20240817009
A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin 50/1000 mg Film-coated Tablets and Reference Product (GALVUS MET (50 MG/1000 MG)) in Healthy Thai Volunteers under Fed Conditions
TCTR20240908005
A Bioequivalence Study of Two Formulations of Fixed Dose Combination Tablets of Vildagliptin 50 mg and Metformin Hydrochloride 1000 mg in Healthy Thai Subjects under Fed Conditions
CTR20243743
在中国健康受试者中随机、开放、两周期、双交叉空腹状态下维格列汀缓释片与维格列汀片的药代动力学比较试验
100 项与 维格列汀 相关的临床结果
登录后查看更多信息
100 项与 维格列汀 相关的转化医学
登录后查看更多信息
100 项与 维格列汀 相关的专利（医药）
登录后查看更多信息
1,267
项与 维格列汀 相关的文献（医药）2025-01-01EXPERIMENTAL NEUROLOGY
Effect of vildagliptin conjugated monometallic nanoparticles and bimetallic nanocomposites on diabetes-induced cognitive deficit
Article
作者: Behera, Anindita ; Pradhan, Sweta Priyadarshini ; Sahu, Pratap Kumar
Oxidative stress is one of the major causes of different metabolic disorders, including diabetes, cardiovascular diseases, neurodegenerative diseases and cancers. Some metabolic disorders like diabetes mellitus leads to secondary complications after micro and macrovascular complications. Some of the most prevalent neurodegenerative diseases, like cognitive impairment and Alzheimer's disease, are found in chronic diabetic patients. The present study is designed to understand the mechanism of interconnection between diabetes mellitus and cognitive deficit using the alloxan model of diabetes-induced cognitive deficit in the rat model. The alloxan monohydrate produces reactive oxygen species, producing superoxide free radicals, hydrogen peroxide and hydroxyl radicals. The hydroxyl radicals ultimately cause the death of beta cells, causing diabetes. Hence, the correlation of oxidative stress and neurodegeneration in cognitive impairment is the trigger for this study. In the present study, we investigate the ameliorative effect of vildagliptin (VLD) and its conjugated nanoparticles against alloxan-associated brain damage due to oxidative stress. The gold (Au), selenium (Se) nanoparticles, and bimetallic (Se@Au) nanocomposites of VLD are synthesized and assessed for improvement in their brain availability. The in-vitro antioxidant evaluation of the VLD and nanoparticles is done using DPPH, ABTS, and FRAP assay. The memory-related neurobehavioral studies, in-vivo antioxidant studies, in-vivo biochemical studies, and histopathological examinations are evaluated in rat brains. The VLD and its nanoformulations exhibited in-vitro and in-vivo antioxidant properties significantly (p < 0.01). They reduced the activity of AChE and nitrite in the alloxan diabetic rats. The bimetallic Se@Au VLDNCs displayed a more protective effect than VLD, VLD-AuNPs, and VLD-SeNPs.
2024-12-20Journal of biomolecular structure & dynamics
Article
作者: Ravi, Vidhya ; Vishnuprasad, Chethala N. ; Chakraborty, Abhijnan ; Kukkupuni, Subrahmanya Kumar ; Sahoo, Sthitaprajna ; Mohan, S Suma ; Garawadmath, Soumya ; Thottappillil, Anjana ; Banvi, Pranav ; Kouser, Sania
Dipeptidyl-peptidase IV (DPP4) inhibitors are an important class of anti-diabetic drugs recognised for their systemic biological actions. Polyherbal preparations like Ayurveda formulations are considered to be ideal sources for discovering novel DPP4 inhibitors owing to their rich phytochemical composition. The current study reports the DPP4 inhibitory potential of a clinically established Ayurvedic anti-diabetic formulation Nisakathakadi Kashaya (NK) using in vitro assay and substantiates it by identifying potential bioactives responsible for DPP4 inhibition using computational biology tools. NK showed a dose-dependent DPP4 inhibition with an IC50 of 2.06 μg GAE/mL, and the molecular docking and simulation studies showed three compounds, namely Terchebin, Locaracemoside B and 1,2,4,6 Tetra o Galloyl Beta D Glucose having stable interactions with DPP4 similar to the standard drug Vildagliptin. Further, for the reason that polyherbal formulations exert a network pharmacology mode of action, in silico analysis was carried out to identify the other putative phytochemical-protein networks modulated by NK. The complex pharmacological network of the formulation was explored further using a subnetwork of diabetes proteins and their relationship with diabetes-associated comorbidities. A number of key targets like TNFα, TGFβ1, SOD1, SOD2, AKT1, DPP4 and GLP1R were identified in the protein-protein interaction network that is vital to diabetic progression and complications. A combination of in vitro and in silico methods allowed us to prove the DPP4 inhibition potential of NK as well as provided insights into the possible pharmacological networking through which NK potentially exerts its systemic effect in diabetes management.Communicated by Ramaswamy H. Sarma.
2024-12-01DIABETES OBESITY & METABOLISM
The impact of vildagliptin as an add‐on therapy on matrix metalloproteinase‐14 levels, liver stiffness and subclinical atherosclerosis in adolescents with type 1 diabetes and non‐alcoholic steatohepatitis: A randomized controlled trial
Article
作者: Ismail, Eman Abdel Rahman ; Elbarbary, Nancy Samir ; Hamed, Eman Tawfik ; ElKabbany, Zeinab Anwar
Abstract:
Aim:
Many patients with type 1 diabetes mellitus (T1DM) met the histological criteria for non‐alcoholic steatohepatitis (NASH), which leads to cardiovascular disease morbidity and mortality. Matrix metalloproteinase‐14 (MMP‐14) is involved in cardiovascular disease and atherosclerosis.
Objectives:
To assess the impact of oral dipeptidyl peptidase‐4 inhibitor, vildagliptin, as adjunctive therapy on NASH in adolescents with T1DM and its effect on glycaemic control, MMP‐14 levels and carotid intima media thickness (CIMT).
Methods:
Sixty adolescents with T1DM and NASH were randomly assigned to receive oral vildagliptin (50 mg once daily) for 6 months or not. Glycated haemoglobin, lipid profile, hepatic steatosis index, triglyceride glucose (TyG) index and MMP‐14 levels were assessed. Transient elastography with controlled attenuation parameter (CAP) was performed together with measuring CIMT.
Results:
By transient elastography, 12 (20%) patients with T1DM with NASH had elevated liver stiffness ≥7 kPa (F2 stage or higher). Baseline MMP‐14 was positively correlated to insulin dose (p = 0.016), triglycerides and TyG index, CIMT, liver stiffness and CAP levels among the studied patients (p < 0.001 for all). After 6 months, patients with T1DM on vildagliptin therapy had significantly lower glycated haemoglobin, lipid profile, hepatic steatosis index and TyG index, as well as MMP‐14 (p < 0.001). CIMT, liver stiffness and CAP were significantly decreased post‐therapy compared with baseline levels and compared with the control group (p < 0.001). Vildagliptin was safe and well‐tolerated.
Conclusions:
Administration of vildagliptin for adolescents with T1DM and NASH improved glycaemic control, dyslipidaemia and MMP‐14 levels and decreased liver stiffness and CIMT; hence, reducing subclinical atherosclerosis and disease progression.
100 项与 维格列汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 欧盟 | 2007-09-25 | |
| 2型糖尿病 | 冰岛 | 2007-09-25 | |
| 2型糖尿病 | 列支敦士登 | 2007-09-25 | |
| 2型糖尿病 | 挪威 | 2007-09-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 1型糖尿病 | 临床3期 | 巴西 | 2014-03-01 | |
| 糖尿病血管病变 | 临床3期 | 英国 | 2010-05-01 | |
| 胰岛素抵抗 | 临床3期 | 英国 | 2010-05-01 | |
| 微血管疾病 | 临床3期 | 英国 | 2010-05-01 | |
| 低血糖 | 临床3期 | 瑞士 | 2006-09-01 | |
| 高血糖 | 临床3期 | 德国 | 2006-02-20 | |
| 葡萄糖耐受不良 | 临床3期 | 美国 | 2005-10-01 | |
| 糖尿病前期 | 临床3期 | 美国 | 2005-04-01 | |
| 非胰岛素依赖型糖尿病2 | 临床3期 | 美国 | 2004-11-01 | |
| 糖尿病 | 临床2期 | 俄罗斯 | 2008-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 憲觸簾醖構顧顧選觸鬱(鹹製顧築廠淵淵蓋鑰鹽) = Three mild hypoglycemic events were reported with the starting dose 觸襯糧壓獵繭憲網襯齋 (築遞鏇鑰願願範憲鬱糧 ) | - | 2024-06-14 | |||
N/A | - | - | 衊獵齋糧醖餘簾願艱簾(窪觸繭蓋鏇膚衊願鏇獵) = 廠襯願蓋顧衊願艱範獵 膚獵積鏇艱衊衊範夢簾 (憲遞網餘壓壓遞鬱鹹鬱 ) | - | 2023-11-15 | ||
临床4期 | 120 | metformin+empagliflozin | 窪齋衊淵窪鏇壓築鹽壓(醖膚憲齋觸壓選鑰壓遞) = 鏇膚積壓餘遞窪選醖壓 築窪襯糧願襯衊壓獵鹹 (蓋構衊齋繭觸夢膚襯鏇, 0.68) | 积极 | 2022-08-17 | ||
metformin+vildagliptin | 窪齋衊淵窪鏇壓築鹽壓(醖膚憲齋觸壓選鑰壓遞) = 製網構鏇餘憲網艱選襯 築窪襯糧願襯衊壓獵鹹 (蓋構衊齋繭觸夢膚襯鏇, 1.57) | ||||||
临床4期 | 346 | Pioglitazone 30mg | 鏇鏇構壓艱廠壓壓憲憲(簾襯網顧鏇醖觸獵簾構) = 淵觸醖壓齋衊觸鹽觸窪 鬱糧繭範選膚餘膚窪顧 (製選構醖壓鬱齋鏇鹽鏇 ) | - | 2022-01-01 | ||
临床4期 | 80 | 鹽鹽範衊選淵選壓鑰齋(淵觸積鬱顧餘築廠夢衊) = 膚鹽築製壓鏇鹹築願淵 鹹衊淵鑰鏇襯鏇積獵構 (廠製範願夢膚廠鬱膚鹽 ) | - | 2020-12-01 | |||
鹽鹽範衊選淵選壓鑰齋(淵觸積鬱顧餘築廠夢衊) = 夢觸構齋範遞窪窪壓顧 鹹衊淵鑰鏇襯鏇積獵構 (廠製範願夢膚廠鬱膚鹽 ) | |||||||
临床4期 | 2,001 | 獵廠選網蓋觸繭壓窪膚(餘繭憲築顧艱淵鬱製壓): adjusted mean change = 19.23 (95% CI, 8.42 ~ 30.03) | 积极 | 2020-09-24 | |||
临床4期 | 2型糖尿病 GLP-1 | 15 | 顧鏇廠鹽窪襯壓淵鏇醖(襯鏇襯醖蓋製餘艱餘簾) = 製窪鹹範顧鏇鑰顧積糧 衊製膚淵網鑰廠鹹窪構 (積築襯遞繭夢觸選選鬱 ) | 积极 | 2019-09-19 | ||
Placebo | 顧鏇廠鹽窪襯壓淵鏇醖(襯鏇襯醖蓋製餘艱餘簾) = 艱餘齋膚壓製鏇範襯觸 衊製膚淵網鑰廠鹹窪構 (積築襯遞繭夢觸選選鬱 ) | ||||||
N/A | - | 網餘襯蓋廠餘壓夢餘鬱(艱簾簾顧鹹鹹繭鏇醖膚) = 鑰夢壓願夢繭糧艱繭簾 積廠繭遞廠窪範鏇廠廠 (網鏇願範獵蓋繭網夢構, 42.6) 更多 | 积极 | 2019-04-30 | |||
網餘襯蓋廠餘壓夢餘鬱(艱簾簾顧鹹鹹繭鏇醖膚) = 糧觸壓願衊網觸醖築積 積廠繭遞廠窪範鏇廠廠 (網鏇願範獵蓋繭網夢構, 54) 更多 | |||||||
N/A | 300 | 淵衊衊窪壓製鏇顧鏇襯(遞構製窪願膚齋餘範鑰) = 醖製簾鹽製網壓鹽築願 鬱淵鏇鹹壓遞糧齋齋鏇 (淵顧餘選糧網糧膚鹹壓, -0.20 ~ -0.90) | - | 2019-04-01 | |||
淵衊衊窪壓製鏇顧鏇襯(遞構製窪願膚齋餘範鑰) = 糧構膚鬱範鏇繭憲願糧 鬱淵鏇鹹壓遞糧齋齋鏇 (淵顧餘選糧網糧膚鹹壓, -0.40 ~ -1.40) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用